Could brain implants tame severe mental illness?

NCT ID NCT06112067

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether deep brain stimulation—implanting electrodes in specific brain areas—can help people with severe, treatment-resistant mental disorders like OCD, schizophrenia, depression, anorexia, gambling addiction, and autism. The study involves 18 participants and measures changes in symptoms using standard rating scales after 12 weeks of stimulation. The goal is to see if this approach is safe and effective for those who haven't found relief from other treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deep brain stimulation (DBS) targeting the ALIC and NAcc brain regions
What this could lead to
If successful, this could offer a new treatment option for people with severe mental disorders that haven't improved with standard therapies.
What could go wrong
This is a small, early-stage study, and results may not apply to everyone. Brain surgery carries risks like infection or bleeding, and the stimulation may not work for all conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Treatment refractory obsessive-compulsive disorder: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 obsessive-compulsive disorder criteria. 3. Fits treatment refractory obsessive-compulsive disorder criteria (both i and ii): i.Treated with at least 3 kinds of serotonin reuptake inhibitors (SSRIs) with at least 2 kinds of 2nd generation antipsychotic medication as enhancement, enough dosage and enough course of treatment, and still no effect or intolerant. ii.While using enough dosage of SSRIs, treated with more than 8\~12 times of Cognitive Behavior Therapy (CBT) or CBT-intolerant. d)Y-BOCS score ≥ 25 in screening period and baseline. e)CGI-S score ≥ 4 in screening period and baseline. f)Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 2. Treatment refractory schizophrenia: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 schizophrenia criteria. 3. Course of disorder ≥ 5 years. 4. Fits treatment refractory schizophrenia criteria, one of the conditions below: i.Treated with more than 2 different anti-psychotic medications (clozapine excluded), enough dosage (equivalent dosage as chlorpromazine ≥ 600mg/day), enough course of treatment (≥ 12 weeks), no effect or intolerant. ii.Treated with enough dosage of clozapine (≥ 300mg/day or blood medication concentration ≥ 350ng/ml, enough course of treatment (≥ 12 weeks), no effect or intolerant. e)PANSS score ≥ 70 in screening period and baseline, and at least 1 item from 5 items (P1, P2, P3, P5, P6) of PANSS positive symptom scale ≥ 4; or at least 3 items from PANSS negative symptom scale (N1\~N7) ≥ 4, or at least 2 items ≥ 5. f)CGI-S ≥ 4 in screening period and baseline. g)GAF ≤ 60 in screening period and baseline. h)Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 3. Treatment refractory bipolar with depression: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 bipolar I or bipolar II criteria, currently with depression episode. 3. Course of disorder ≥ 2 years. 4. Fits treatment refractory bipolar with depression criteria (treated with two different kinds of treatment below, enough dosage and enough course of treatment ≥ 8 weeks, and cannot acquire symptom cure for 8 consecutive weeks, either i or ii): i.Used at least two medications (alone) among Olanzapine (10-20mg/d) + Fluoxetine (20-60mg/d), Quetiapine (200-600mg/d), Lurasidone (40-160mg/d), Lamotrigine (200-400mg/d) ii.Used at least one medication above (alone), and used one of medication above with another medication among Lamotrigine (200-400mg/d), Valproate (1000-2000mg/d) and lithium salt (blood lithium reaches 0.8mmol/L). e)Upon medication treatment, electroconvulsive therapy ≥ 12 times, no effect or failed (such as intolerant). f)Fits severe symptom criteria: i.Depression episode ≥ 12 weeks in screening period. ii.MADRS score ≥ 26 in screening period and baseline. iii.GCI-BP score ≥ 4 in screening period and baseline. iv.YMRS score ≥ 12 in screening period and baseline. g)Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 4. Treatment refractory anorexia nervosa: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 anorexia nervosa criteria, consider both restricting type and binge-eating/purging type. 3. 10 ≤ BMI \< 16 in screening period and baseline. 4. Fits treatment refractory anorexia nervosa criteria (both i, ii, iii and iv): i.Course of disorder ≥ 5 years, severe and sustained anorexia nervosa. ii.With ≥ 3 times repeated inpatient history and bad treatment effect (can't complete treatment or immediate relapse after treatment). iii.Through systemic nutrient treatment, medication (SSRIs and/or anti-psychotics), psychotherapies (such as reinforced CBT, FBT treatment), no effect or intolerant. iv.Worsened instability of clinical treatment, refuse treatment or bad reaction to reinforced treatment, last for more than 1 year, with more than 2 times of involuntary food intake. e)Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 5. Gambling disorder: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Course of disorder ≥ 2 years. 3. Diagnosed as gambling disorder based on DSM-5, fits medium or severe diagnostic standard (≥ 6 terms) 4. Received systemic treatment (such as medication and social mental intervention) but still has iterative thoughts of impulse or gambling behaviors. 5. Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 6. Adult autism: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 autism spectrum disorder diagnostic standard, and there's severe, life-threatening iterative behaviors, and independently evaluated by two psychiatric doctors. 3. AuBC score ≥ 62 in screening period and baseline. 4. CGI-S score ≥ 4 in screening period and baseline. 5. Course of disorder ≥ 10 years, received systemic behavior intervention or training ( such as critical reaction training, cognitive behavior intervention, language expression training, demonstration method, natural environment training, patriarch training, social skill training, intervention based on story tales, etc. ) but failed, or intolerant. 6. Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. Exclusion Criteria: 1. With mental disorders including physical mental disorders, paranoid personality disorder, delayed mental development etc. 2. Through clinical evaluation by investigators, there exists significant suicide behavior risk. 3. From screening period to baseline, patients who has significant improvement in evaluation scores: 1. Obsessive compulsive disorder: Y-BOCS score decreased (or improved) ≥ 20% 2. Schizophrenia: PANSS score decreased (or improved) ≥ 20% 3. Bipolar with depression: MADRS score decreased (or improved) ≥ 20% 4. Anorexia nervosa: BMI improved ≥ 20% 5. Gambling: through evaluation by investigators, online gambling behavior is significantly improved 6. Adult autism: AuBC score decreased (or improved) ≥ 20%. 4. With severe or unstable cardiovascular, inspiratory, liver, kidney, blood, endocrine, neural system or other system disorders. 5. Has neural system disorders including physical brain disorders, brain trauma, treatment-refractory seizure etc. 6. During screening period or baseline, abnormalities in patient's physical examination, laboratory examination, electrocardiogram examination, imaging examination have significant clinical meaning, and patients who are considered unfit by investigators. 7. Implanted artificial cochlea, pacemaker, similar single-side or double-side products or experienced other physical surgeries within half a year that are considered to have effect on this trial by investigators. 8. DBS implant surgery taboos present and is considered unfit by investigators. 9. Diagnosed as HIV positive. 10. Female in gestation, lactation, or blood HCG / urine gestation test positive. Or patients who can't take effective contraception actions during the trial. Or patients planning to birth or give birth after the trial begins for 3 months. 11. Currently involved or involved in other medication or medical device clinical trials 3 months before the screening period. 12. Other patients who are considered unfit by investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autism spectrum disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai Mental Health Center

    RECRUITING

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.